Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Development of Nanotechnology -Based Drugs and its Guidance Prof. Dr. Basavaraj K. Nanjwade M. Pharm., Ph.D Department of Pharmaceutics KLE University College of Pharmacy BELGAUM-590010 E-mail: [email protected] Cell No: 00919742431000 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 1 CONTENTS Nanotechnology Nanoparticle Dendrimer Liposomes Micelles Nanoemulsions Nanocrystals Primary Particle Metal Colloids Guidance for Industry Nontechnology Based Products 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 2 Definitions Nanomaterial/Nanoscale Material: Any material with at least one dimension smaller than 100 nm. Nanomedicine: The use of nanoscale applications Characterization: Physicochemical properties 15/04/ 2012 materials evaluation of FDP on Nanotechnology, VTU, Belgaum. for relevant medical drug 3 Nanotechnology Commercialization 1. Consumer product applications, including cosmetics and sunscreens 2. Food applications, including dietary supplements 3. Medical applications, including drugs and drug delivery devices. 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 4 Medical Applications Product Developed Applications Rapamune® Elan’s An immunosuppressant Emend® Elan’s Anti-nausea Estrasorb® Elan’s Topical estrogen therapy Megace® ES Elan’s Stimulate appetite TriCor® Elan’s Cholesterol-lowering Abraxane® APP Breast cancer Doxil® Alza Anti-cancer Acticoat® Smith & Nephew Antimicrobial SilvaGard AcryMed, Inc., Antimicrobial 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 5 Nanotechnology • The understanding and control of matter at dimensions between approximately 1 to 100 nanometers, where unique phenomena enable novel applications. • (Source: National Nanotechnology Initiative Definition) 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 6 Types of pharmaceutical nanosystems 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 7 Nanoparticle • Nano-object with all three external dimensions at the nanoscale that is the size range from approximately 1 nm to 100 nm. • Polymeric nanoparticle platforms are characterized by their physicochemical structures including solid nanoparticles, nanoshell, dendrimer, polymeric micelle, and polymer-drug conjugates. 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 8 Nanoparticle TEM (a, b, and c) images of prepared mesoporous silica nanoparticles with mean outer diameter: (a) 20nm, (b) 45nm, and (c) 80nm. SEM (d) image corresponding to (b). The insets are a high magnification of mesoporous silica particle 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 9 Dendrimer A polymer in which the atoms are arranged in many branches and subbranches along a central backbone of carbon atoms. 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 10 Dendrimer 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 11 Liposomes Vesicles composed of one or more bilayers of amphiphatic lipid molecules enclosing one or more aqueous compartments. 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 12 Liposomes 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 13 Micelles Self-assembling nanosized colloidal particles with a hydrophobic core and hydrophilic shell currently used for the solubilization of various poorly soluble pharmaceuticals. 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 14 Micelles 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 15 Nanoemulsions • Emulsions with droplet size in the nanometer scale. • Emulsion is a thermodynamically unstable system consisting of at least two immiscible liquid phases, one of which is dispersed as globules (the dispersed phase), in the other liquid phase (the continued phase), stabilized by the presence of an emulsifying agent. 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 16 Nanoemulsions 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 17 Nanocrystals Nanoscale solid formed with a periodic lattice of atoms, ions, or molecules. 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 18 Nanocrystals 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 19 Primary Particle Smallest identifiable particulate system. 15/04/ 2012 subdivision FDP on Nanotechnology, VTU, Belgaum. in a 20 Primary Particle 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 21 Metal Colloids • Metal nanoparticles in colloidal systems where the term colloidal refers to a state of subdivision. • This implies that the molecules or polymolecular particles are dispersed in a medium and have at least in one direction a dimension roughly between 1 nm and 1μm or, in a system, have discontinuities at distances of that order. • For example, silver, gold, titanium dioxide, zinc oxide, and iron oxide. 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 22 Metal Colloids 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 23 Polymer Colloids 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 24 Guidance for Nano-Industry I. Chemistry Manufacturing and Control II. Human Pharmacokinetics and Bioavailability III. Labeling 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 25 I. Chemistry Manufacturing and Control A. B. C. D. Description and Composition Physicochemical Properties Description of Manufacturing Process and Process Control Control of Excipients: Lipid Components 1. 2. 3. 4. Description and Characterization Manufacture Specifications Stability E. Control of Drug Product: Specifications F. Stability G. Changes in Manufacturing 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 26 Description and Composition • The components of liposome drug products are the drug substance, the lipids, and other inactive ingredients. • The pharmacological and toxicological properties and the quality of these drug products can vary significantly with changes in the formulation, including the lipid composition. 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 27 Physicochemical Properties • Morphology of the liposome, including lamellarity determination, if applicable • Volume of entrapment in liposomal vesicles • Particle size (mean and distribution profile) • Phase transition temperature • Spectroscopic data, as applicable • In vitro release of the drug substance from the liposome drug product • osmotic properties • light scattering index 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 28 Description of Manufacturing Process and Process Control • Liposome drug products are sensitive to changes in the manufacturing conditions, including changes in scale. • If there are changes in critical manufacturing parameters, complete characterization of the liposome drug product is recommended and in vivo studies may be warranted. 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 29 Control of Excipients: Lipid Components 1. Description and Characterization 2. Manufacture 3. Specifications 4. Stability 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 30 Control of Drug Product: Specifications • Physicochemical parameters of the liposome determined to be critical to product quality for each batch. • Assay for encapsulated and unencapsulated (i.e., free) drug substance. • Degradation products related to the lipids. • Assay of lipid components. • In vitro test for release of drug substance from the liposome. 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 31 Stability • The physical stability of liposome drug products is a function of the integrity and the size distribution of the lipid vesicles. • Liposomes are susceptible to fusion, aggregation, and leakage of the encapsulated drug substance during storage. • Liposome drug products should be evaluated for stability of the encapsulated drug substance as well as stability of the lipids that compose the liposomal bilayer. 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 32 Changes in Manufacturing • Liposome drug products are a relatively new dosage form, it is not possible to provide recommendations on the type of information that should be generated to demonstrate that the change has not adversely affected the quality of the drug product. • The extent of the information and documentation to be developed and submitted to support a change should depend on the types of manufacturing changes and the stage of manufacturing at which the changes occur. 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 33 II. Human Pharmacokinetics and Bioavailability A. B. C. D. E. Bioanalytical Methods In Vivo Integrity (Stability) Considerations Protein Binding In Vitro Stability Pharmacokinetics and Bioavailability 1. 2. 3. Mass Balance Study Pharmacokinetic Studies Additional Pharmacokinetic Studies a. b. c. Food-Effect Studies Drug Interactions and /or Special Populations Exposure-response Studies 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 34 Bioanalytical Methods • Validated bioanalytical methods should be used when evaluating the pharmacokinetics and bioavailablity of a drug substance. • For liposome drug products the bioanalytical method should also be capable of measuring encapsulated and unencapsulated drug substance. 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 35 In Vivo Integrity (Stability) Considerations • In addition to the general stability considerations of the drug substance in a biological fluid, the stability of the liposome in vivo should be considered. • A single-dose study is recommended to assess the in vivo stability of the liposome. • The concentration-time profile should be evaluated at multiple time points over an adequate period of time. • The concentration of encapsulated and unencapsulated drug substance should be determined at each sampling time point. 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 36 Protein Binding • The stability of liposomes in vivo can be affected by interactions with lipoproteins and other proteins in the blood. • Interactions of liposomes with serum proteins and lipoproteins can be dependent on the type of lipids used in formulating the liposomes. • The protein (including lipoprotein) binding of the drug substance and liposome drug product should be determined over the expected therapeutic concentration range. • The major binding proteins should be identified. 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 37 In Vitro Stability • An in vitro test that measures the release of the drug substance from the liposome can be important for assessing the (1) Quality of a liposome drug product, (2) Adequacy of the process controls, (3) Release characteristics of the product over time, and (4) The effect of CMC changes e.g., minor manufacturing process changes or change in site of manufacture. 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 38 Pharmacokinetics and Bioavailability 1. Mass Balance 2. Pharmacokinetic Studies 3. Additional Pharmacokinetic Studies a. Food-Effect Studies b. Drug Interaction and /or special Populations c. Exposure-Response Studies 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 39 III. Labeling A. Product Name B. Cautionary Notes and Warning C. Dosage and Administration 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 40 Product Name • The product name should include the established name, dosage form, terminology to describe that it is a liposome drug product, and, if desired, a proprietary (i.e., brand) name. • The descriptive terminology should include the term liposome and, when appropriate, such terms as Type A, Type B, and Type C, to distinguish one liposome product from other liposomal formulations of the same drug substance that are not therapeutically equivalent. • For example: BrandX (Acetaminophen) Liposome-Type A For Injection 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 41 Cautionary Notes and Warning • A cautionary note should be included in the description section of the labeling regarding the fact that liposome drug products may behave differently from nonliposome drug products. • A warning should be included in the labeling that the liposome drug product is not equivalent to or cannot be substituted for other drug products containing the same drug substance. 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 42 Dosage and Administration • This information should be provided for both unloaded lyophilized liposomes that are reconstituted with a drug substance-containing solution at the time of use, as well as products in which the drug substance is loaded into the liposome by the manufacturer and then lyophilized. • Other issues that should be addressed, as warranted, include storage conditions for the reconstituted drug, robustness of the liposome drug product under varied reconstitution conditions (e.g., degree of shaking), and appropriateness of using in-line filters. 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 43 Nanotechnology Product Evaluating Questions 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 44 Nanotechnology Product Evaluating Questions 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 45 Template for CDER Nanotechnology Drug Product Database Entry 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 46 Nanotechnology Product Review Flow Chart 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 47 Nanotechnology Product Review Flow Chart 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 48 Common Techniques for Characterization • Morphology • Surface • Chemical • Others 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 49 Morphology Properties Common Techniques Size (primary particle) TEM, SEM, AFM, XRD Size (primary/aggregate/agglomerate) TEM, SEM, AFM, DLS, FFF, AUC, CHDF, XDC, HPLC, DMA(1) Size distribution EM, SEM, AFM, DLS, AUC, FFF, HPLC, SMA Molecular weight SLS, AUC, GPC Structure/Shape TEM, SEM, AFM, NMR Stability (3D structure) DLS, AUC, FFF, SEM, TEM 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 50 Surface P roperties Common Techniques Surface area BET Surface charge SPM, GE, Titration methods Zeta potential LDE, ESA, PALS Surface coating composition SPM, XPS, MS, RS, FTIR, NMR Surface coating coverage AFM, AUC, TGA Surface reactivity Varies with nanomaterial Surface-core interaction SPM, RS, ITC, AUC, GE Topology SEM, SPM, MS 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 51 Chemical Properties Common Techniques Chemical composition (core, surface) XPS, MS, AAS, ICP-MS, RS, FTIR, NMR Purity ICP-MS, AAS, AUC, HPLC, DSC Stability (chemical) MS, HPLC, RS, FTIR Solubility (chemical) Varies with nanomaterial Structure (chemical) NMR, XRD Crystallinity XRD, DSC Catalytic activity Varies with nanomaterial 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 52 Other Properties Common Techniques Drug loading MS, HPLC, UV-Vis, varies with nanomaterial Drug potency/functionality Varies with nanomaterial In vitro release (detection) UV-Vis, MS, HPLC, varies with nanomaterial Deformability AFM, DMA(2) 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 53 Abbreviations 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 54 THANK YOU E-mail: [email protected] Cell No: 0091-9742431000 15/04/ 2012 FDP on Nanotechnology, VTU, Belgaum. 55